Suppr超能文献

慢性乙型肝炎病毒感染自然史中中医证候模式及其与乙肝表面抗原水平的关联

Traditional Chinese Medicine Syndrome Patterns and Their Association with Hepatitis B Surface Antigen Levels during the Natural History of Chronic Hepatitis B Virus Infection.

作者信息

Xie He-Ping, Liu Zhi-Ping, Zhang Jiong-Shan, Dai Min, Xiao Ge-Min, Wu Wei-Kang, Yang Hong-Zhi

机构信息

Department of Integrative Chinese and Western Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China.

Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China.

出版信息

Evid Based Complement Alternat Med. 2018 Oct 2;2018:7482593. doi: 10.1155/2018/7482593. eCollection 2018.

Abstract

The aim of this study is to investigate traditional Chinese medicine syndrome (TCMS) patterns and their association with hepatitis B surface antigen (HBsAg) levels during the natural history of chronic hepatitis B virus infection (CHB). Patients were categorized according to the phase of CHB, as follows: immune tolerance (ITP); immune clearance (ICP); low or nonreplication (LRP); reactivation (RAP); hepatic cirrhosis (HC); and primary liver cancer (PLC). TCMS patterns were classified among the following types: spleen-kidney deficiency (SKD); liver-qi depression (LQD); damp-heat in liver-gallbladder (LGDH); liver-kidney deficiency (LKD); and blood stasis blocking collateral (BSBC). HBsAg levels and other serological indicators were quantified for all patients and their association with TCMS was statistically analyzed and determined. Two hundred and eighty-nine patients with CHB were included. During the natural history of CHB, TCMS patterns were statistically different among the different phases ( 0.001). The most frequently occurring syndromes among the six progressive phases were SKD, LGDH, LKD, LGDH, BSBC, and LGDH, respectively. The predominant patterns in the inactive stage (ITP + LRP), active stage (ICP + RAP), and late or advanced stage (HC + PLC) were SKD (31%), LGDH (51.8%) and BSBC (34.4%), respectively. Median HBsAg levels were also statistically different among the five patterns of TCMS ( 0.001). The highest HBsAg levels were observed in SKD (4.48 log IU/mL). Medium levels were in LQD (3.91 log IU/mL) and LGDH (3.90 log IU/mL). The lowest HBsAg levels were in LKD (3.60 log IU/mL) and the second lowest levels in BSBC (3.81 log IU/mL). In addition, HBsAg levels in LKD and BSBC were significantly lower than those in SKD, LQD, and LGDH ( < 0.05 or 0.001). TCMS was altered during the natural history of CHB and correlated with HBsAg titers. This study could provide further insight into the therapy of CHB.

摘要

本研究旨在探讨慢性乙型肝炎病毒感染(CHB)自然史过程中的中医证候类型及其与乙肝表面抗原(HBsAg)水平的关系。根据CHB的阶段对患者进行分类,如下:免疫耐受期(ITP);免疫清除期(ICP);低复制或非复制期(LRP);再激活期(RAP);肝硬化(HC);以及原发性肝癌(PLC)。中医证候类型分为以下几种:脾肾亏虚(SKD);肝郁气滞(LQD);肝胆湿热(LGDH);肝肾亏虚(LKD);以及瘀血阻络(BSBC)。对所有患者的HBsAg水平和其他血清学指标进行量化,并对其与中医证候的相关性进行统计分析和判定。纳入了289例CHB患者。在CHB自然史过程中,不同阶段的中医证候类型存在统计学差异(P<0.001)。六个进展阶段中最常见的证候分别为SKD, LGDH, LKD, LGDH, BSBC和LGDH。非活动期(ITP + LRP)、活动期(ICP + RAP)和晚期或终末期(HC + PLC)的主要证候类型分别为SKD(31%)、LGDH(51.8%)和BSBC(34.4%)。五种中医证候类型的HBsAg水平中位数也存在统计学差异(P<0.001)。SKD患者的HBsAg水平最高(4.48 log IU/mL)。LQD(3.91 log IU/mL)和LGDH(3.90 log IU/mL)患者的HBsAg水平中等。LKD患者的HBsAg水平最低(3.60 log IU/mL),BSBC患者的HBsAg水平次之(3.81 log IU/mL)。此外,LKD和BSBC患者的HBsAg水平显著低于SKD、LQD和LGDH患者(P<0.05或P<0.001)。CHB自然史过程中中医证候发生改变,并与HBsAg滴度相关。本研究可为CHB的治疗提供进一步的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7188/6189657/2142fb85ef6e/ECAM2018-7482593.001.jpg

相似文献

2
Chinese medicine syndrome distribution of chronic hepatitis B virus carriers in immunotolerant phase.
Chin J Integr Med. 2014 Feb;20(2):94-100. doi: 10.1007/s11655-013-1569-5. Epub 2014 Mar 6.
7
Serum cytokine profiling analysis for zheng differentiation in chronic hepatitis B.
Chin Med. 2015 Aug 27;10:24. doi: 10.1186/s13020-015-0055-8. eCollection 2015.
9
Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B.
Clin Microbiol Infect. 2014 Nov;20(11):1173-80. doi: 10.1111/1469-0691.12739. Epub 2014 Jul 29.
10
Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.
Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2125-2129. doi: 10.22034/APJCP.2018.19.8.2125.

引用本文的文献

1
Silicosis: from pathogenesis to therapeutics.
Front Pharmacol. 2025 Jan 29;16:1516200. doi: 10.3389/fphar.2025.1516200. eCollection 2025.
2
Kushenin Combined with Adefovir Dipivoxil or Entecavir for Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
Evid Based Complement Alternat Med. 2021 Feb 25;2021:8856319. doi: 10.1155/2021/8856319. eCollection 2021.

本文引用的文献

1
Elimination of Hepatitis B: Is It a Mission Possible?
BMC Med. 2017 Mar 15;15(1):53. doi: 10.1186/s12916-017-0820-x.
2
Chitosan and Sodium Alginate Combinations Are Alternative, Efficient, and Safe Natural Adjuvant Systems for Hepatitis B Vaccine in Mouse Model.
Evid Based Complement Alternat Med. 2016;2016:7659684. doi: 10.1155/2016/7659684. Epub 2016 Jul 14.
5
Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.
World J Gastroenterol. 2014 Jul 21;20(27):9178-84. doi: 10.3748/wjg.v20.i27.9178.
6
Chinese medicine syndrome distribution of chronic hepatitis B virus carriers in immunotolerant phase.
Chin J Integr Med. 2014 Feb;20(2):94-100. doi: 10.1007/s11655-013-1569-5. Epub 2014 Mar 6.
8
HBsAg quantification: useful for monitoring natural history and treatment outcome.
Liver Int. 2014 Feb;34 Suppl 1:97-107. doi: 10.1111/liv.12403.
9
The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma.
J Hepatol. 2014 May;60(5):975-84. doi: 10.1016/j.jhep.2013.12.014. Epub 2013 Dec 19.
10
HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers.
Liver Int. 2014 Aug;34(7):e238-45. doi: 10.1111/liv.12345. Epub 2013 Oct 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验